Vanessa Salinas-Luna
Pediatric Hematology-Oncology · Orange, CANPI 1952597858
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Sanofi at 57.6% of the total. 2025 is the largest year on record at $115,826, 5.7 times the $20,170 reported in 2019. Among pediatric hematology-oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 420 payments — averaging $818.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$198K
- Bayer$70K
- Genentech USA, Inc.$26K
- Shire North American Group Inc$14K
- Biomarin Pharmaceutical Inc.$7K
- Pfizer$5K
- plus $23K from 21 others
Across 216 payments — averaging $901.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$59K
- Global Blood Therapeutics, Inc.$55K
- Novo Nordisk AS$45K
- Bayer$33K
- Sanofi US Services Inc.$2K
What the payments were for
- Consulting fees$77,55123%
- Speaking & faculty fees$202,35459%
- Travel & lodging$52,44815%
- Food & beverage$11,0313%
- Education$2730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 170 | $197,848 |
| Bayer | 75 | $70,172 |
| Genentech USA, Inc. | 40 | $26,024 |
| Shire North American Group Inc | 12 | $14,076 |
| Biomarin Pharmaceutical Inc. | 14 | $7,494 |
| Pfizer | 13 | $5,408 |
| Octapharma USA, Inc. | 13 | $4,552 |
| CSL Behring | 9 | $3,860 |
| Genentech, Inc. | 8 | $3,353 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $3,195 |
| Global Blood Therapeutics, Inc. | 5 | $2,238 |
| Bristol Myers Squibb | 1 | $1,902 |
| Novo Nordisk AS | 4 | $1,509 |
| Novo Nordisk | 19 | $719 |
| Spark Therapeutics, Inc. | 5 | $284 |
| Agios Pharmaceuticals, Inc. | 6 | $262 |
| Novartis | 3 | $169 |
| Rigel Pharmaceuticals, Inc. | 2 | $140 |
| AstraZeneca | 1 | $122 |
| HEMA Biologics, LLC | 2 | $87 |
| Chiesi USA, Inc. | 3 | $51 |
| Bio Products Laboratory USA, Inc. | 2 | $47 |
| Vertex | 2 | $45 |
| Grifols USA, LLC | 2 | $43 |
| Sobi, Inc | 1 | $23 |
| Emmaus Medical, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$343,657 in reported general payments places this provider in the 95th percentile of 307 pediatric hematology-oncology providers in California.
See all pediatric hematology-oncology providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PromactaEltrombopag Olamine | 12 | $75,481 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisPromacta | $169 | $75,48112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 307 pediatric hematology-oncology providers in California.
Other pediatric hematology-oncology in Orange
- Arash MahajerinOrange$249K
- Amit SoniOrange$70K
- Esteban GomezOrange$56K
- Diane NugentOrange$55K
- van HuynhOrange$37K
- Mariko SatoOrange$21K
- Philip PizzoPalo Alto$2.6M
- Vinod BalasaMadera$508K
- Akshat JainRedlands$447K
- Noah FedermanLos Angeles$399K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.